Precigen Inc.

1 day ago · prnewswire.com

Designation has the potential to accelerate development of current and future therapies built on Precigen's AdenoVerse platform GERMANTOWN, Md., Sept. 21, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that the United States Food and Drug Administration (FDA) granted platform technology designation to the AdenoVerse® immunotherapeutic platform, which is used in the company's first commercial product, PAPZIMEOS®.

5 days ago · defenseworld.net

Celldex Therapeutics (NASDAQ: CLDX - Get Free Report) and Precigen (NASDAQ: PGEN - Get Free Report) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, risk, profitability, analyst recommendations and valuation. Profitability This table compares Celldex Therapeutics and Precigen's

8 days ago · zacks.com

PGEN's Papzimeos is driving strong early sales, while European expansion and pipeline progress could shape the stock's growth outlook.

12 days ago · zacks.com

Papzimeos is fueling Precigen's growth, with sales more than doubling sequentially in Q2 and demand continuing to rise in 2026.

28 days ago · accessnewswire.com

Biotech in the News: The Longview The Company's New Drug, the First FDA-Approved Therapy for Recurrent Respiratory Papillomatosis (RRP), is Delivering Strong Commercial Traction While Highlighting the Broader Potential of Its Proprietary AdenoVerse Therapeutic Platform in HPV-Associated Cancers GERMANTOWN, MD / ACCESS Newswire / August 25, 2026 / For Germantown, MD-based Precigen Inc. (NASDAQ:PGEN), the second quarter marked a commercial inflection. PAPZIMEOS (zopapogene imadenovec-drba) generated $53.1 million in net product revenue-more than double the prior quarter-and helped the company achieve quarterly profitability.

1 month ago · zacks.com

Precigen's Papzimeos drives rapid revenue growth, while market exclusivity, global expansion and its pipeline add long-term potential.

1 month ago · zacks.com

Does Precigen, Inc. (PGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

2 months ago · seekingalpha.com

Precigen, Inc. is upgraded to a Strong Buy, driven by surging PAPZIMEOS revenues and FDA approval for recurrent respiratory papillomatosis (RRP). PGEN achieved profitability in Q2 2026 with PAPZIMEOS revenues doubling quarter-over-quarter to $53.1 million and secured seven years of U.S. market exclusivity. Potential European approval of PAPZIMEOS and expansion of the AdenoVerse Immunotherapy platform, notably PRGN-2009, could unlock significant new market opportunities.

2 months ago · seekingalpha.com

Precigen, Inc. (PGEN) Q2 2026 Earnings Call Transcript

2 months ago · marketbeat.com

Precigen NASDAQ: PGEN reported a sharp increase in second-quarter revenue from its PAPZIMEOS launch, with the company reaching quarterly profitability less than a year after the therapy's August 2025 FDA approval for adults with recurrent respiratory papillomatosis, or RRP.